Generated November 16, 2026 at 8:30 PM ET
· Covers November 16 trading day
· 10 of 337 ready 8-Ks selected
· AI-assisted overview
The day's 8-K filings were dominated by financial distress and listing problems. Cable One disclosed an NYSE delisting notice and skipped a roughly $10 million interest payment on $503 million of 2030 notes, Optimum's CSC Holdings withheld about $102.5 million in interest across three note issues and entered a 30-day grace period, Children's Place filed Chapter 11 with $282 million in DIP financing and was halted ahead of Nasdaq delisting, Lakewood-Amedex faces Nasdaq delisting after a sustained sub-$1.00 bid, and OZ Vision said it will restate FY2025 and FY2026 results after a $12.6 million license was deemed invalid. Deal news included Aon closing its $17.0 billion USI acquisition, Merck KGaA agreeing to buy Rapid Micro Biosystems for $0.75 per share, and the Black Hills–NorthWestern all-stock merger closing under the new Bright Horizon Energy name. On the regulatory side, the FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab BLA, while CG Oncology reported Phase 3 PIVOT-006 results showing a 68% reduction in recurrence risk.
regulatory
negative
materiality 0.95
November 16, 2026, 4:41 PM ET
Cable One gets NYSE delisting notice and skips $10M interest payment on $503M 4.00% notes due 2030
- NYSE notice dated Nov 13, 2026: 30-trading-day average global market cap below $50M while last reported stockholders' equity was also below $50M (Section 802.01B).
- Cable One has 45 days to submit a cure plan; if NYSE accepts, CABO keeps trading during an 18-month cure period, otherwise delisting proceedings could begin.
- On Nov 16, 2026 the company did not make a scheduled ~$10M interest payment on ~$503M outstanding 4.00% senior notes due 2030; a 30-day grace period applies.
SMMT
Summit Therapeutics Inc.
regulatory
negative
materiality 0.92
November 16, 2026, 6:08 AM ET
FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC
- FDA said substantial evidence of effectiveness is not established without a statistically significant overall survival benefit; PFS benefit alone failed to support a positive benefit-risk profile.
- HARMONi met its PFS primary endpoint, but the primary OS analysis showed only a positive trend that was not statistically significant.
- Post-hoc longer follow-up showed OS hazard ratio of 0.76 across the full, Asian and western patient populations.
M&A
positive
materiality 0.85
November 16, 2026, 4:51 PM ET
Aon closes $17.0B USI acquisition; Sicard named President, $4B term loans drawn
- Completed the USI acquisition for a total purchase price of $17.0B; USI is the tenth-largest U.S. insurance broker with ~$3B in annual revenue and 10,500+ team members across ~200 U.S. offices.
- Mike Sicard, USI CEO since 2007, named President of Aon and global CEO of middle market across Aon, NFP and USI; base salary $1M, 150% bonus target, $5M FY2027 LPP target.
- Sicard rolled over 1,052,632 vested USI stock options into Aon restricted share awards valued at ~$50M at closing, cliff vesting on the third anniversary.
RPID
RAPID MICRO BIOSYSTEMS, INC.
M&A
positive
materiality 0.85
November 16, 2026, 4:14 PM ET
Merck KGaA to buy Rapid Micro Biosystems for $0.75/share cash in tender offer
- Merck KGaA units Parent and EMD Holdings NewCo II signed a merger agreement on Nov 16, 2026 to buy all RPID Class A and Class B shares for $0.75 cash per share.
- Tender offer runs 10 business days initially, conditioned on majority of Class A shares plus pre-funded warrant shares; merger then closes under DGCL 251(h) with no stockholder vote.
- RPID board unanimously approved and recommends the deal; holders of ~19.58% of shares, including all directors and some executives, signed tender and support agreements.
LABT
Lakewood-Amedex Biotherapeutics Inc.
regulatory
negative
materiality 0.82
November 16, 2026, 4:35 PM ET
Nasdaq to delist Lakewood-Amedex (LABT) after 30 days below $1.00; hearing sought
- Nov 10, 2026 Nasdaq staff letter: closing bid price stayed below $1.00 for 30 consecutive business days, Sept 29 through Nov 9, 2026.
- Company is not eligible for a compliance cure period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year.
- Unless a hearing is requested by Nov 17, 2026, trading is suspended at the open on Nov 19, 2026 and Nasdaq files Form 25-NSE to delist.
BKH
BLACK HILLS CORP /SD/
M&A
positive
materiality 0.80
November 16, 2026, 6:45 AM ET
Black Hills–NorthWestern all-stock merger closes; new Bright Horizon Energy (HZN) serves 2.2M customers in eight states
- NorthWestern holders received 0.98 Bright Horizon shares per NWE share; about 60.2 million new shares issued, with cash in lieu of fractional shares.
- Combined company serves 2.2 million electric and natural gas customers across eight states; NorthWestern is now a wholly owned Bright Horizon subsidiary.
- Brian Bird, ex-NorthWestern CEO, named President and CEO; Crystal Lail CFO, Marne Jones COO, Jeff Berzina Chief Accounting Officer; Darren Nakata Chief Legal Officer.
PLCE
Childrens Place, Inc.
other material
negative
materiality 0.95
November 16, 2026, 8:00 AM ET
Children's Place files Chapter 11, secures $282M DIP; Nasdaq to delist, trading halted Nov 16
- Chapter 11 petitions filed Nov 8, 2026 in U.S. Bankruptcy Court for New Jersey, jointly administered as Case No. 26-22682 (SLM); interim DIP order entered Nov 10.
- DIP facilities: $166M ABL revolver with Wells Fargo as agent and $116M term loan with Crystal Financial (SLR Credit Solutions); interim obligations capped near $131M.
- DIP term pricing is one-month Term SOFR (2.00% floor) plus 8.25%; ABL is base rate plus 3.50%; maturities Jan 29, 2027 (ABL) and Mar 1, 2027 (term).
other material
negative
materiality 0.95
November 16, 2026, 6:14 AM ET
OZ Vision to restate FY2025 and FY2026 financials after $12.6M NSAC license deemed invalid
- Board concluded on Nov. 2, 2026 that audited financials for fiscal years ended June 30, 2025 and 2026 should not be relied upon due to intangible-asset recognition errors.
- Auditor Boladale Lawal & Co flagged $12,568,890 NSAC license as material misstatement; NSAC said license No. 147 was invalid and not transferred.
- The license was issued for 2018 to Final Fight Championship, owned by Mr. Orsat Zovko, and states it is not transferable; Producers Lifetime rights had no historical cost basis.
other material
positive
materiality 0.90
November 16, 2026, 8:15 AM ET
CG Oncology PIVOT-006 Phase 3 wins: 68% recurrence risk cut (HR 0.32) in NMIBC
- Cretostimogene cut recurrence risk 68% vs control in adjuvant intermediate-risk/high-grade Ta ≤3cm NMIBC; HR 0.32 (95% CI 0.23-0.45; p<0.0001), median follow-up 17 months.
- No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations; safety consistent with prior studies.
- Initial BLA in BCG-unresponsive NMIBC broadened per FDA feedback to include high-grade papillary-only disease plus CIS; completion now expected by end of March 2027.
OPTU
Optimum Communications, Inc.
debt
negative
materiality 0.90
November 16, 2026, 8:00 AM ET
Optimum's CSC Holdings skips $102.5M interest payment, enters 30-day grace period amid $22B restructuring talks
- CSC Holdings withheld ~$56.25M on its 11.250% 2028 notes, $33.75M on its 4.500% 2031 guaranteed notes and $12.50M on its 5.000% 2031 notes, all due November 16, 2026.
- Each indenture carries a 30-day grace period before non-payment becomes an Event of Default; no cross-default triggered and the notes are not accelerated unless payment is missed past the deadline.
- Company reported $1.1 billion of consolidated cash and equivalents as of September 30, 2026, and says it continues paying operating debts and vendors in the ordinary course.